Reduction in hospitalisation for heart failure with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from the EMPA-REG OUTCOME trial
Significance of speckle-tracking in identifying subclinical myocardial injury of young patients with Type1 Diabetes mellitus without cardiovascular disease.